Systemic Erythropoietin Injection in Patients Having Optic Atrophy
Overview
- Phase
- Phase 1
- Intervention
- Systemic erythropoietin injection
- Conditions
- Optic Atrophy
- Sponsor
- Alexandria University
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- Visual acuity
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy.
Detailed Description
The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy. The intervention is systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days). Follow up after one month and three months by recording visual acuity and electro physiological studies.
Investigators
Mohamed Fahmy Doheim
Prinicipal investigator
Alexandria University
Eligibility Criteria
Inclusion Criteria
- •Post papilledemic optic atrophy patients
Exclusion Criteria
- •Refuse to give an informed consent
Arms & Interventions
Systemic erythropoietin injections
The study included 10 patients diagnosed as post papilledemic optic atrophy
Intervention: Systemic erythropoietin injection
Outcomes
Primary Outcomes
Visual acuity
Time Frame: 3 months
VIsual acuity assessed at the follow up
Pattern visual evoked Potential .
Time Frame: 3 months
Pattern visual evoked Potential .in both eyes to use data of the normal fellow eye as patients' internal control
Pattern electroretinogram
Time Frame: 3 months
Pattern electroretinogram in both eyes to use data of the normal fellow eye as patients' internal control